Please ensure Javascript is enabled for purposes of website accessibility

Why Athersys Stock Jumped Today

By Keith Speights - Mar 31, 2021 at 3:45PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech's partner completed enrollment in a key clinical study.

What happened

Shares of Athersys (ATHX 4.38%) were jumping 10.9% higher as of 3:17 p.m. EDT on Wednesday. The solid gain came after the company announced that its partner Healios completed enrollment in a clinical study being conducted in Japan evaluating regenerative stem cell therapy candidate MultiStem in treating acute respiratory distress syndrome (ARDS) caused by pneumonia.

So what

Completion of enrollment in a clinical study doesn't always serve as a catalyst for biotech stocks. In this case, though, investors seem to be optimistic that Healios' study will be positive and that Athersys will also be successful with its own study of MultiStem in treating ARDS.

Two scientists in a lab

Image source: Getty Images.

Healios' clinical trial includes two patient cohorts. The larger cohort enrolled 30 patients with the goal of evaluating MultiStem in treating pneumonia-induced ARDS. The other cohort enrolled five patients with ARDS resulting from COVID-19. Athersys' own U.S. study includes participants with ARDS stemming from COVID-19 and other pathogens. 

There currently aren't any effective drug treatments available for ARDS. Physicians have only limited intervention alternatives for the disorder that's characterized by severe inflammation in the lungs.

Now what

Athersys expects top-line results from Helios' study of MultiStem later this year. Helios also should announce results from its late-stage study of Athersys' stem cell therapy in treating ischemic stroke in 2021. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Athersys, Inc. Stock Quote
Athersys, Inc.
ATHX
$0.19 (4.38%) $0.01

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
332%
 
S&P 500 Returns
118%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.